top of page

Biocon expands Yesintek biosimilar licensing rights to nine additional international markets

Immagine del redattore: nuaxia
nuaxia
27 ott
Tempo di lettura: 2 min

Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint.


The agreement with Janssen Sciences Ireland covers Yesintek, a proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan.


The new rights extend Biocon's previously established market-entry arrangements, although financial terms were not disclosed and commercial launches remain dependent on applicable national regulatory approvals.

Field

Content

Article Type

Deals

Companies

Biocon; Janssen Sciences Ireland

Deal Type

International biosimilar licensing and market-entry agreement

Licensee

Biocon

Licensing Counterparty

Janssen Sciences Ireland

Product

Yesintek

Active Ingredient

Ustekinumab

Reference Medicine

Stelara

Product Category

Proposed biosimilar

Therapeutic Area

Immunology; immune-mediated inflammatory diseases

Newly Covered Markets

Australia; Brazil; China; Hong Kong; Israel; Mexico; New Zealand; South Korea; Kazakhstan

Number of Additional Markets

9

Existing Market Context

Previously secured market-entry rights in the United States and other major regions

Financial Terms

Not disclosed

Upfront Payment

Not disclosed

Milestone Payments

Not disclosed

Royalties

Not disclosed

Regulatory Status

Country-specific regulatory approvals remain necessary where applicable

Commercial Launch Timing

Not confirmed in supplied summary

Announcement Date

26 October 2026

What Happened

Biocon entered an agreement with Janssen Sciences Ireland expanding Yesintek market-entry rights to nine additional international territories.

Why It Matters

The agreement increases the potential geographic reach of Biocon's ustekinumab biosimilar and could support future biosimilar competition in additional markets.

Strategic Rationale

Expand Biocon's international biosimilar commercialisation opportunities through additional licensed territories.

Regulatory Distinction

The announcement concerns licensing and market-entry rights, not nine new marketing authorisations.

Key Takeaway

Biocon has secured Yesintek rights across nine additional markets, with actual commercialisation subject to national regulatory requirements.

What to Watch

Country-specific approvals, launch schedules, pricing, reimbursement decisions, supply arrangements and market uptake.

Primary Source

Biocon

Primary Source URL

https://www.biocon.com/biocon-secures-market-entry-for-yesintek-a-proposed-biosimilar-to-stelara-in-additional-global-markets/

Relevant Date

26 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

Commenti

Valutazione 0 stelle su 5.
Non ci sono ancora valutazioni

Aggiungi una valutazione
bottom of page